By Will Feuer


Zoetis Inc. cut its full-year adjusted earnings guidance and lowered the high-end of its range for sales, citing negative effects from recent changes to foreign-exchange rates.

The animal-medicine company, spun off by Pfizer Inc. in 2013, said it now expects adjusted earnings of between $4.97 a share and $5.05 a share, down from its prior guidance of $4.99 a share to $5.09 a share.

Full-year revenue is expected to be between $8.225 billion and $8.325 billion, narrowed from $8.225 billion to $8.375 billion. Unadjusted earnings are expected to be between $4.65 a share and $4.75 a share, narrowed from a range of $4.65 a share to $4.77 a share.


Write to Will Feuer at


(END) Dow Jones Newswires

August 04, 2022 07:51 ET (11:51 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
過去 株価チャート
から 8 2022 まで 9 2022 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 9 2021 まで 9 2022 Pfizerのチャートをもっと見るにはこちらをクリック